upadacitinib (Rinvoq) For the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more DMARDs. Upadacitinib may be used as monotherapy or in combination with methotrexate
upadacitinib (Rinvoq) Treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs). upadacitinib may be used as monotherapy or in combination with methotrexate.
upadacitinib (Rinvoq) For treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs). Upadacitinib may be used as monotherapy or in combination with methotrexate.
upadacitinib (Rinvoq) Treatment of active ankylosing spondylitis in adult patients who have responded inadequately to conventional therapy.
upadacitinib (Rinvoq) Treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, loss of response or were intolerant to either conventional therapy (CT) or a biologic agent.
upadacitinib (Rinvoq) Treatment of active non-radiographic axial spondyloarthritis (nr-axSpA) in adult patients with objective signs of inflammation (OSI) as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI), who have responded inadequately to nonsteroidal anti-inflammatory drugs (NSAIDs)
upadacitinib (Rinvoq) Treatment of moderate to severe atopic dermatitis (AD) in adults and adolescents 12 years and older who are candidates for systemic therapy.
upadacitinib (Rinvoq) Treatment of adult patients with moderately to severely active Crohn’s disease who have had an inadequate response or, lost response or were intolerant to either conventional therapy or a biologic agent, or for whom such therapies are not advisable.
February 2021 decisions news release The Scottish Medicines Consortium (SMC), which advises on newly licensed medicines for use by NHSScotland, has today (Monday 8 February) published advice on four new medicines.
December 2022 decisions news release The Scottish Medicines Consortium (SMC), which advises on the use of newly licensed medicines by NHSScotland, has today (Monday 12 December), published advice on four new medicines.
April 2022 decisions news release Advice on three new medicines has today (Monday 11 April) been published by the Scottish Medicines Consortium.
February 2023 decisions news release The Scottish Medicines Consortium (SMC), which advises on newly-licensed medicines for use by NHSScotland, has today (Monday 13 February) published advice on five new medicines.
November 2022 decisions news release The Scottish Medicines Consortium (SMC), which advises on the use of newly licensed medicines by NHSScotland, has today (Monday 7 November), published advice on six new medicines.
June 2023 decisions news release The Scottish Medicines Consortium (SMC), which advises on newly-licensed medicines for use by NHSScotland, has today (Monday, June 12) published advice on six medicines.
